Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

Core Viewpoint - Ipsen has entered into a definitive share purchase agreement to acquire ImCheck Therapeutics, focusing on the development of next-generation immuno-oncology therapies, particularly the lead program ICT01 for acute myeloid leukemia (AML) patients who cannot tolerate intensive chemotherapy [1][3]. Company Overview - Ipsen is a global biopharmaceutical company dedicated to transformative medicines in oncology, rare diseases, and neuroscience, with nearly 100 years of development experience [11]. - ImCheck Therapeutics is a private French biotechnology company developing immunotherapeutic antibodies targeting butyrophilins, with a focus on enhancing the immune response against cancer [13][14]. Acquisition Details - The acquisition involves a payment of 350 million euros at closing, with potential total consideration up to 1 billion euros based on regulatory approvals and sales milestones [5][8]. - The transaction is expected to close by the end of Q1 2026, pending regulatory approvals [6]. Clinical Program Focus - The lead program ICT01 is a first-in-class monoclonal antibody targeting BTN3A, which has shown promising interim data in the Phase I/II EVICTION trial for AML, achieving high treatment responses [3][8]. - ICT01 is designed to activate γ9δ2 T cells, enhancing the immune response against tumors, and has received Orphan Drug Designations from both the U.S. FDA and European Medicines Agency [1][10]. Market Need - There is a significant unmet medical need for new therapies in AML, particularly for patients who are unfit for intensive chemotherapy, highlighting the urgency for innovative treatments [2].